Anti-KLB Peptide Conjugate (Hengrui)

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameAnti-KLB Peptide Conjugate (Hengrui)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon receptor agonists +[4] 
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon receptor +[4] 
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Hengrui Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Hengrui Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A